Key result
TAVR availability for severe symptomatic aortic stenosis was highly cost-effective, yielding an incremental cost-effectiveness ratio of $8,533 and a 395% rate of return.
Why the study?
The study evaluated the availability of TAVR to determine its value across all severe symptomatic aortic stenosis patients, especially those untreated due to concerns regarding invasive SAVR and its impact on active aging.
Does TAVR availability improve cost-utility and cost-benefit in US elderly severe symptomatic aortic stenosis patients?
Does TAVR availability improve cost-utility and cost-benefit in US elderly severe symptomatic aortic stenosis patients?
Effect estimate: ICER $8,533; RoR 395%
TAVR availability represents strong value-for-money per patient and population-wide in the US, primarily by increasing treatment uptake among previously untreated patients.
No takes yet. Share an insight, caveat, or question.
TAVR availability may yield high economic returns in SSAS; modeling leaves open real-world adoption effects.
Sevilla et al. (2022) studied Severe symptomatic aortic stenosis (SSAS). TAVR availability vs. TAVR not available (only SAVR and medical management) was evaluated on Incremental cost-effectiveness ratio (ICER) and rate of return (RoR) (ICER $8,533; RoR 395%). TAVR availability for severe symptomatic aortic stenosis was highly cost-effective, yielding an incremental cost-effectiveness ratio of $8,533 and a 395% rate of return.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: